{"schema_version":"secwatch.filing_event.v1","accession":"0001723128-23-000023","form_type":"8-K","ticker":"AMRX","cik":"0001723128","company_name":"Amneal Pharmaceuticals, Inc.","filed_at":"2023-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.236164+00:00","generated_at":"2026-06-15T02:38:37.954954+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Amneal shareholders elect all director nominees, approve compensation and incentive plan","bullets":["All 11 director nominees elected with at least 84% of votes cast in favor.","Advisory say-on-pay proposal approved with 97.4% of votes cast in favor.","Ratification of Ernst & Young as auditor approved with 99.4% of votes cast.","Amended & Restated 2018 Incentive Award Plan approved with 93.3% of votes cast."],"urls":{"canonical":"https://secwatch.observer/filing/0001723128-23-000023","json":"https://secwatch.observer/filing/0001723128-23-000023.json","markdown":"https://secwatch.observer/filing/0001723128-23-000023.md","text":"https://secwatch.observer/filing/0001723128-23-000023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1723128/000172312823000023/0001723128-23-000023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1723128/000172312823000023/amrx-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T02:38:37.954954+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"14a6855b312cc8ba3de36b6316d795afad85d551","claim":"Amneal Pharmaceuticals, Inc. shareholders approved To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers at the 2023-05-09 meeting.","evidence_excerpt":"Proposal 2 : To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers: For Against Abstain Broker Non-Votes 227,413,821 3,098,184 680,576 25,513,061","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1723128/000172312823000023/0001723128-23-000023-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-09"}],"fact_type":"shareholder_vote"},{"claim_id":"7845d93073b2db6ee600a4b8960402ce25040930","claim":"Amneal Pharmaceuticals, Inc. shareholders approved To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-05-09 meeting.","evidence_excerpt":"Proposal 3 : To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023: For Against Abstain Broker Non-Votes 254,931,713 1,641,294 132,635 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1723128/000172312823000023/0001723128-23-000023-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-09"}],"fact_type":"shareholder_vote"},{"claim_id":"7e03857d972e06bc061c6b1ad6da3b1752efb0cd","claim":"Amneal Pharmaceuticals, Inc. shareholders approved To elect the following director nominees to hold office until the 2024 Annual Meeting of Stockholders and until their respective successors are elected and qualified at the 2023-05-09 meeting.","evidence_excerpt":"Proposal 1 : To elect the following director nominees to hold office until the 2024 Annual Meeting of Stockholders and until their respective successors are elected and qualified: For Against Abstain Broker Non-Votes Emily Peterson Alva 229,279,380 1,816,706 96,495 25,513,061 Deb Autor 229,602,211 1,483,770 106,600 25,513,061 J. Kevin Buchi 197,910,568 33,179,505 102,508 25,513,061 Jeff George 198,211,840 32,879,658 101,083 25,513,061 John Kiely 196,066,358 35,022,385 103,838 25,513,061 Paul Meister 212,151,263 18,932,673 108,645 25,513,061 Ted Nark 228,742,967 2,217,364 232,250 25,513,061 Chintu Patel 229,230,849 1,865,246 96,486 25,513,061 Chirag Patel 229,182,342 1,913,165 97,074 25,513,061 Gautam Patel 227,239,534 3,785,347 167,700 25,513,061 Shlomo Yanai 229,147,164 1,938,034 107,383 25,513,061","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1723128/000172312823000023/0001723128-23-000023-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-09"}],"fact_type":"shareholder_vote"},{"claim_id":"a9d48024f2fc37bb60ee9e8a6af9e107aa43c4f0","claim":"Amneal Pharmaceuticals, Inc. shareholders approved To approve the Amended & Restated 2018 Incentive Award Plan at the 2023-05-09 meeting.","evidence_excerpt":"Proposal 4 : To approve the Amended & Restated 2018 Incentive Award Plan: For Against Abstain Broker Non-Votes 215,730,063 15,006,306 456,212 25,513,061","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1723128/000172312823000023/0001723128-23-000023-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-09"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}